查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1504260

液態切片的全球市場:評估 - 各產品，各技術，各樣品類型，循環生物標記，各用途，各使用方法，各終端用戶，各地區，機會，預測，2017～2031年

Liquid Biopsy Market Assessment, By Product, By Technology, By Sample Type, By Circulating Biomarker, By Application, By Usage, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 233 Pages | 商品交期: 3-5個工作天內

價格

全球液體切片市場規模預計將從 2023 年的 62.9 億美元增至 2031 年的 162.3 億美元，在 2024-2031 年預測期間複合年增長率為 12.58%。癌症發生率的增加、新技術的引入以及研發活動投資的增加支持了市場的成長。

液體活檢提供的各種優勢促使該技術的使用越來越多。液體活檢為患者提供了便利和耐受性，並且有可能在成像測試出現或誘發臨床症狀之前很久就檢測出治療抗藥性或疾病進展。液體活檢的非侵入性使得疾病管理變得容易，並透過簡單、快速且可重複的測試來提高患者的可接受性。

液體活檢檢測迄今已獲得包括美國食品和藥物管理局 (US FDA) 在內的多個管理和監管機構的批准，已用於治療卵巢癌、乳腺癌、肺癌和結直腸癌，它可用於監測前列腺癌患者的疾病進展、確定標靶治療並測量治療效果。

本報告提供全球液態切片市場相關調查，提供市場概要，以及各產品，各技術，各樣品類型，循環生物標記，各用途，各使用方法，各終端用戶，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 調查手法

第2章 計劃的範圍和定義

第3章 摘要整理

第4章 全球液態切片市場展望，2017～2031年

  • 市場規模·預測
  • 各產品
  • 各技術
  • 各樣品類型
  • 依循環生物標記
  • 各使用方法
  • 各用途
  • 各終端用戶
  • 各地區
  • 各企業市場佔有率(%)、2023年

第5章 全球液態切片市場展望，各地區(2017～2031年)

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第6章 市場製圖，2023年

第7章 宏觀環境和產業結構

  • 供給需求分析
  • 進出口分析
  • 價值鏈分析
  • PESTEL分析
  • 波特的五力分析

第8章 市場動態

第9章 法規結構和革新

第10章 主要加入企業的形勢

第11章 價格分析

第12章 案例研究

第13章 主要加入企業的展望

  • F. Hoffmann-La Roche Ltd.
  • Guardant Health, Inc.
  • Bio-Rad Laboratories, Inc.
  • QIAGEN N.V.
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • Natera, Inc.
  • Biocept, Inc.
  • Myriad Genetics, Inc.
  • Foundation Medicine

第14章 策略性建議

第15章 公司概要·免責聲明

Product Code: MX11536

Global liquid biopsy market is projected to witness a CAGR of 12.58% during the forecast period 2024-2031F, growing from USD 6.29 billion in 2023 to USD 16.23 billion in 2031F. The market's growth is supported by the increasing prevalence of cancer, the introduction of novel technologies, and rising investments in research and development activities.

Due to the various advantages offered by liquid biopsy, the applications of the technique are increasing. It offers convenience and tolerability for patients and has the potential to detect treatment resistance and disease progression long before the condition appears on imaging scans or triggers clinical symptoms. The non-invasive nature of liquid biopsies allows for easy disease management and boosts patient acceptability by allowing for easy and quick, repeatable tests.

The liquid biopsy assays approved so far by the different governing and regulatory bodies, including the United States Food and Drug Administration (US FDA), can be used for monitoring disease progression, identifying targeted treatments, and gauging the therapy response in patients with ovarian, breast, lung, colorectal, and prostate cancer, among other solid cancers.

Technological advancements in liquid biopsy are another major factor supporting the market's growth. An artificial intelligence (AI)-guided approach has shown significant sensitivity in predicting cancer recurrence, according to a new study published in the journal "Nature" in June 2024. The article showed that the machine learning model can detect circulating tumor DNA based on DNA sequencing data from blood tests of patients with high accuracy and sensitivity in patients with colorectal cancer, melanoma, lung cancer, precancerous colorectal polyps, and breast cancer.

Introduction of Novel Technologies Boosts Market Growth

The rising investments by various companies and startups towards introducing novel technologies are expected to bolster the global liquid biopsy market growth. For instance, Twist Bioscience Corp, one of the leading synthetic biology companies known for developing synthetic DNA-based products, launched a cfDNA library preparation kit for applications in liquid biopsy in February 2024. The kit is built to maximize the number of cfDNA molecules and increase confidence in the sensitivity and accuracy of liquid biopsy tests. The kit adds to the company's portfolio of tools designed to support the research and development of liquid biopsy assays.

Such efforts have also supported the development of artificial intelligence-powered tools that are sensitive to predicting cancer recurrence. A team of scientists trained a machine learning model for analyzing ctDNA based on the DNA sequencing data from blood tests. The technology was tested in patients with colorectal cancer, breast cancer, lung cancer, precancerous colorectal polyps, and melanoma. It achieved a significant signal-to-noise enhancement, thus enabling the detection of cancer recurrence.

Increasing Prevalence of Cancer Supports Market Expansion

The rise in the number of cancer cases across the globe is one of the major factors boosting the global liquid biopsy market demand. According to the estimates of the World Health Organization (WHO), over 35 million new cases of cancer are expected to occur in 2050. This rise is providing lucrative growth opportunities to the market as liquid biopsies aid in tracking and identifying cancer non-invasively. Liquid biopsies also find applications in various stages of cancer management, including response monitoring, therapy selection, and early cancer identification. The advancements in liquid biopsy, such as next-generation sequencing (NGS) and digital polymerase chain reaction (dPCR), have aided in improving the specificity and sensitivity of biomarker identification. The popularity of liquid biopsy is increasing among physicians as it aids in identifying cancer at an early stage. They can also examine CTCs and ctDNA released in the circulation by tumors to determine tumor-specific markers and genetic changes linked with early-stage malignancies.

North America Accounts for Significant Market Share

The growth of the market in North America is supported by the strong presence of key market players and an advanced healthcare system, acceptance of new technologies, rising cases of cancer, and increasing investments in research and development activities. The National Cancer Institute (NIH) estimates that 2,001,140 new cancer cases will be diagnosed in the United States in 2024, and 611,720 individuals will die from the disease. Furthermore, the increasing investments towards upgrading healthcare technology and infrastructure in the United States provide lucrative growth opportunities to the market.

The introduction of new products by healthcare and biotechnology companies based in the region is further supporting the expansion of the market in North America. In June 2022, Caris Life Sciences, Inc., a leading molecular science and technology company known for delivering and developing innovative solutions for revolutionizing healthcare, introduced its Caris Assure liquid biopsy assay. The blood-based molecular profiling assay analyzes the whole transcriptome (cfRNA) and the whole exome (cfDNA) of 22,000 genes from a simple blood sample, including the Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and Loss of Heterozygosity (LOH).

Cancer Applications Account for Significant Liquid Biopsy Market Share

The increasing prevalence of different types of cancer and growing awareness about the various benefits offered by liquid biopsy are propelling the segment's expansion. The non-invasive approach of liquid biopsies to manage and diagnose cancer is further bolstering the adoption of the technique for cancer applications. Additionally, due to the rise in the number of cases of colorectal cancer and the various advantages offered by liquid biopsy for colorectal cancer screening as compared to invasive methods such as colonoscopy and traditional non-invasive methods that include screening with a stool sample, liquid biopsy has the potential for integrating into clinical practice to manage and diagnose colorectal cancer effectively. According to the estimates of the Colorectal Cancer Alliance, approximately 150,000 Americans are diagnosed with colorectal cancer every year.

Furthermore, the rising research activities to develop blood tests that can accurately detect early-stage cancer further support the segment's growth. A blood test was developed by the City of Hope Duarte Cancer Center researchers in California, United States, that analyzes small RNA bits released by the tumors. The study, which included 1,000 participants from various regions across the globe, showed that the test was able to detect late accurately- and early-stage pancreatic cancer in a diverse group of individuals.

Future Market Scenario (2024-2031F)

As per the global liquid biopsy market analysis, the market is expected to grow significantly in the coming years. Liquid biopsy has gained popularity over the past few years and has provided a repeatable and minimally invasive method of describing and detecting cancers. The procedure has the potential to transform cancer care by categorizing cancer-specific genomic alterations; this, in turn, aids in the identification of resistance markers, early detection, and residual assessment of diseases. Additionally, the rising investments in clinical trials to evaluate and determine the benefits of liquid biopsy are further expected to aid the expansion of the market. For instance, the Case Comprehensive Cancer Center in Cleaveland, Ohio, United States, is conducting a study to determine if liquid biopsy reduces the time for treatment of advanced nonsquamous non-small cell lung cancer. The interventional study is expected to conclude in August 2024.

Key Players Landscape and Outlook

Rising collaborations between companies and startups specializing in diagnostics and developing tumor treatments are bolstering the global liquid biopsy market size. In June 2024, EVIIVE and Ymmunobio AG announced a collaboration to develop an innovative liquid biopsy with the help of extracellular vesicles for enhancing precision in disease monitoring and detection. The collaboration aims to advance the field of precision medicine and enhance the efficacy and accuracy of patient monitoring and disease detection. The novel liquid biopsy will use the unique properties of extracellular vesicles to provide a precise and non-invasive diagnostic tool and bring forward the next generation of diagnostic assays for patients with cancer to provide them with more reliable treatment guidance. Such collaborations and partnerships showcase the commitment of different companies and startups toward improving patient outcomes and innovation by providing advanced therapeutic and diagnostic solutions.

Table of Contents

1. Research Methodology

2. Project Scope and Definitions

3. Executive Summary

4. Global Liquid Biopsy Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Product
    • 4.2.1. Instruments
    • 4.2.2. Kits and Consumables
  • 4.3. By Technology
    • 4.3.1. Single-Gene Analysis Using PCR
    • 4.3.2. Multi-Gene Parallel Analysis Using NGS
  • 4.4. By Sample Type
    • 4.4.1. Blood/Plasma
    • 4.4.2. Others
  • 4.5. By Circulating Biomarker
    • 4.5.1. Circulating Tumor Cells
    • 4.5.2. Cell-Free DNA
    • 4.5.3. Circulating Tumor DNA
    • 4.5.4. Extracellular Vesicles
  • 4.6. By Application
    • 4.6.1. Cancer Applications
      • 4.6.1.1. Breast Cancer
      • 4.6.1.2. Lung Cancer
      • 4.6.1.3. Gastric Cancer
      • 4.6.1.4. Prostate Cancer
      • 4.6.1.5. Melanoma
      • 4.6.1.6. Colorectal Cancer
      • 4.6.1.7. Others
    • 4.6.2. Non-Cancer Applications
    • 4.6.3. Organ Transplant
    • 4.6.4. Infectious Disease Testing
    • 4.6.5. Non-Invasive Prenatal Testing
    • 4.6.6. Monitoring
      • 4.6.6.1. Treatment Monitoring
      • 4.6.6.2. Recurrence Monitoring
    • 4.6.7. Others
  • 4.7. By Usage
    • 4.7.1. Clinical Use
    • 4.7.2. Research Use
  • 4.8. By End-user
    • 4.8.1. Hospitals
    • 4.8.2. Diagnostic Laboratories
    • 4.8.3. Academic and Research Centers
    • 4.8.4. Others
  • 4.9. By Region
    • 4.9.1. North America
    • 4.9.2. South America
    • 4.9.3. Europe
    • 4.9.4. Asia-Pacific
    • 4.9.5. Middle East and Africa
  • 4.10. By Company Market Share (%), 2023

5. Global Liquid Biopsy Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Product
      • 5.1.2.1. Instruments
      • 5.1.2.2. Kits and Consumables
    • 5.1.3. By Technology
      • 5.1.3.1. Single-Gene Analysis Using PCR
      • 5.1.3.2. Multi-Gene Parallel Analysis Using NGS
    • 5.1.4. By Sample Type
      • 5.1.4.1. Blood/Plasma
      • 5.1.4.2. Others
    • 5.1.5. By Circulating Biomarker
      • 5.1.5.1. Circulating Tumor Cells
      • 5.1.5.2. Cell-Free DNA
      • 5.1.5.3. Circulating Tumor DNA
      • 5.1.5.4. Extracellular Vesicles
    • 5.1.6. By Application
      • 5.1.6.1. Cancer Applications
        • 5.1.6.1.1. Breast Cancer
        • 5.1.6.1.2. Lung Cancer
        • 5.1.6.1.3. Gastric Cancer
        • 5.1.6.1.4. Prostate Cancer
        • 5.1.6.1.5. Melanoma
        • 5.1.6.1.6. Colorectal Cancer
        • 5.1.6.1.7. Others
      • 5.1.6.2. Non-Cancer Applications
      • 5.1.6.3. Organ Transplant
      • 5.1.6.4. Infectious Disease Testing
      • 5.1.6.5. Non-Invasive Prenatal Testing
      • 5.1.6.6. Monitoring
        • 5.1.6.6.1. Treatment Monitoring
        • 5.1.6.6.2. Recurrence Monitoring
      • 5.1.6.7. Others
    • 5.1.7. By Usage
      • 5.1.7.1. Clinical Use
      • 5.1.7.2. Research Use
    • 5.1.8. By End-user
      • 5.1.8.1. Hospitals
      • 5.1.8.2. Diagnostic Laboratories
      • 5.1.8.3. Academic and Research Centers
      • 5.1.8.4. Others
    • 5.1.9. United States*
      • 5.1.9.1. Market Size & Forecast
        • 5.1.9.1.1. By Value
        • 5.1.9.1.2. By Volume
      • 5.1.9.2. By Product
        • 5.1.9.2.1. Instruments
        • 5.1.9.2.2. Kits and Consumables
      • 5.1.9.3. By Technology
        • 5.1.9.3.1. Single-Gene Analysis Using PCR
        • 5.1.9.3.2. Multi-Gene Parallel Analysis Using NGS
      • 5.1.9.4. By Sample Type
        • 5.1.9.4.1. Blood/Plasma
        • 5.1.9.4.2. Others
      • 5.1.9.5. By Circulating Biomarker
        • 5.1.9.5.1. Circulating Tumor Cells
        • 5.1.9.5.2. Cell-Free DNA
        • 5.1.9.5.3. Circulating Tumor DNA
        • 5.1.9.5.4. Extracellular Vesicles
      • 5.1.9.6. By Application
        • 5.1.9.6.1. Cancer Applications
          • 5.1.9.6.1.1. Breast Cancer
          • 5.1.9.6.1.2. Lung Cancer
          • 5.1.9.6.1.3. Gastric Cancer
          • 5.1.9.6.1.4. Prostate Cancer
          • 5.1.9.6.1.5. Melanoma
          • 5.1.9.6.1.6. Colorectal Cancer
          • 5.1.9.6.1.7. Others
        • 5.1.9.6.2. Non-Cancer Applications
        • 5.1.9.6.3. Organ Transplant
        • 5.1.9.6.4. Infectious Disease Testing
        • 5.1.9.6.5. Non-Invasive Prenatal Testing
        • 5.1.9.6.6. Monitoring
          • 5.1.9.6.6.1. Treatment Monitoring
          • 5.1.9.6.6.2. Recurrence Monitoring
        • 5.1.9.6.7. Others
      • 5.1.9.7. By Usage
        • 5.1.9.7.1. Clinical Use
        • 5.1.9.7.2. Research Use
      • 5.1.9.8. By End-user
        • 5.1.9.8.1. Hospitals
        • 5.1.9.8.2. Diagnostic Laboratories
        • 5.1.9.8.3. Academic and Research Centers
          • 5.1.9.8.3.1. Others
    • 5.1.10. Canada
    • 5.1.11. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East and Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Product
  • 6.2. By Technology
  • 6.3. By Sample Type
  • 6.4. By Circulating Biomarker
  • 6.5. By Application
  • 6.6. By Usage
  • 6.7. By End-user
  • 6.8. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat From New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (By Value, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. F. Hoffmann-La Roche Ltd.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products and Services
    • 13.1.4. Financials (As Reported)
    • 13.1.5. Key Market Focus and Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Guardant Health, Inc.
  • 13.3. Bio-Rad Laboratories, Inc.
  • 13.4. QIAGEN N.V.
  • 13.5. Illumina, Inc.
  • 13.6. Thermo Fisher Scientific Inc.
  • 13.7. Natera, Inc.
  • 13.8. Biocept, Inc.
  • 13.9. Myriad Genetics, Inc.
  • 13.10. Foundation Medicine

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 4. Global Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 5. Global Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 6. Global Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 7. Global Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 8. Global Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 9. Global Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 10. Global Liquid Biopsy Market Share (%), By Region, 2017-2031F
  • Figure 11. North America Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 12. North America Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 13. North America Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 14. North America Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 15. North America Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 16. North America Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 17. North America Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 18. North America Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 19. North America Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 20. North America Liquid Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 21. United States Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. United States Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 23. United States Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 24. United States Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 25. United States Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 26. United States Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 27. United States Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 28. United States Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 29. United States Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 30. Canada Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 31. Canada Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 32. Canada Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 33. Canada Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 34. Canada Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 35. Canada Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 36. Canada Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 37. Canada Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 38. Canada Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 39. Mexico Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 40. Mexico Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 41. Mexico Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 42. Mexico Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 43. Mexico Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 44. Mexico Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 45. Mexico Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 46. Mexico Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 47. Mexico Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 48. Europe Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 49. Europe Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 50. Europe Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 51. Europe Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 52. Europe Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 53. Europe Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 54. Europe Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 55. Europe Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 56. Europe Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 57. Europe Liquid Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 58. Germany Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. Germany Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 60. Germany Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 61. Germany Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 62. Germany Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 63. Germany Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 64. Germany Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 65. Germany Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 66. Germany Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 67. France Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 68. France Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 69. France Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 70. France Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 71. France Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 72. France Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 73. France Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 74. France Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 75. France Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 76. Italy Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Italy Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 78. Italy Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 79. Italy Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 80. Italy Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 81. Italy Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 82. Italy Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 83. Italy Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 84. Italy Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 85. United Kingdom Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 86. United Kingdom Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 87. United Kingdom Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 88. United Kingdom Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 89. United Kingdom Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 90. United Kingdom Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 91. United Kingdom Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 92. United Kingdom Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 93. United Kingdom Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 94. Russia Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. Russia Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 96. Russia Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 97. Russia Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 98. Russia Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 99. Russia Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 100. Russia Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 101. Russia Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 102. Russia Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 103. Netherlands Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 104. Netherlands Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 105. Netherlands Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 106. Netherlands Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 107. Netherlands Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 108. Netherlands Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 109. Netherlands Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 110. Netherlands Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 111. Netherlands Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 112. Spain Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 113. Spain Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 114. Spain Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 115. Spain Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 116. Spain Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 117. Spain Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 118. Spain Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 119. Spain Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 120. Spain Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 121. Turkey Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 122. Turkey Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 123. Turkey Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 124. Turkey Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 125. Turkey Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 126. Turkey Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 127. Turkey Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 128. Turkey Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 129. Turkey Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 130. Poland Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 131. Poland Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 132. Poland Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 133. Poland Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 134. Poland Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 135. Poland Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 136. Poland Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 137. Poland Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 138. Poland Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 139. South America Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 140. South America Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 141. South America Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 142. South America Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 143. South America Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 144. South America Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 145. South America Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 146. South America Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 147. South America Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 148. South America Liquid Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 149. Brazil Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 150. Brazil Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 151. Brazil Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 152. Brazil Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 153. Brazil Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 154. Brazil Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 155. Brazil Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 156. Brazil Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 157. Brazil Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 158. Argentina Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 159. Argentina Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 160. Argentina Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 161. Argentina Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 162. Argentina Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 163. Argentina Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 164. Argentina Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 165. Argentina Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 166. Argentina Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 167. Asia-Pacific Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. Asia-Pacific Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 169. Asia-Pacific Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 170. Asia-Pacific Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 171. Asia-Pacific Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 172. Asia-Pacific Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 173. Asia-Pacific Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 174. Asia-Pacific Liquid Biopsy Market Share (%), By Usage, In USD Billion, 2016-2030
  • Figure 175. Asia-Pacific Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 176. Asia-Pacific Liquid Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 177. India Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 178. India Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 179. India Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 180. India Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 181. India Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 182. India Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 183. India Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 184. India Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 185. India Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 186. China Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 187. China Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 188. China Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 189. China Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 190. China Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 191. China Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 192. China Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 193. China Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 194. China Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 195. Japan Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 196. Japan Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 197. Japan Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 198. Japan Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 199. Japan Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 200. Japan Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 201. Japan Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 202. Japan Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 203. Japan Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 204. Australia Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 205. Australia Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 206. Australia Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 207. Australia Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 208. Australia Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 209. Australia Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 210. Australia Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 211. Australia Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 212. Australia Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 213. Vietnam Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 214. Vietnam Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 215. Vietnam Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 216. Vietnam Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 217. Vietnam Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 218. Vietnam Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 219. Vietnam Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 220. Vietnam Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 221. Vietnam Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 222. South Korea Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 223. South Korea Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 224. South Korea Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 225. South Korea Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 226. South Korea Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 227. South Korea Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 228. South Korea Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 229. South Korea Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 230. South Korea Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 231. Indonesia Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 232. Indonesia Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 233. Indonesia Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 234. Indonesia Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 235. Indonesia Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 236. Indonesia Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 237. Indonesia Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 238. Indonesia Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 239. Indonesia Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 240. Philippines Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 241. Philippines Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 242. Philippines Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 243. Philippines Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 244. Philippines Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 245. Philippines Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 246. Philippines Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 247. Philippines Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 248. Philippines Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 249. Middle East & Africa Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 250. Middle East & Africa Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 251. Middle East & Africa Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 252. Middle East & Africa Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 253. Middle East & Africa Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 254. Middle East & Africa Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 255. Middle East & Africa Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 256. Middle East & Africa Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 257. Middle East & Africa Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 258. Middle East & Africa Liquid Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 259. Saudi Arabia Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 260. Saudi Arabia Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 261. Saudi Arabia Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 262. Saudi Arabia Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 263. Saudi Arabia Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 264. Saudi Arabia Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 265. Saudi Arabia Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 266. Saudi Arabia Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 267. Saudi Arabia Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 268. UAE Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 269. UAE Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 270. UAE Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 271. UAE Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 272. UAE Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 273. UAE Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 274. UAE Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 275. UAE Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 276. UAE Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 277. South Africa Liquid Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 278. South Africa Liquid Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 279. South Africa Liquid Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 280. South Africa Liquid Biopsy Market Share (%), By Technology, 2017-2031F
  • Figure 281. South Africa Liquid Biopsy Market Share (%), By Sample Type, 2017-2031F
  • Figure 282. South Africa Liquid Biopsy Market Share (%), By Circulating Biomarker, 2017-2031F
  • Figure 283. South Africa Liquid Biopsy Market Share (%), By Application, 2017-2031F
  • Figure 284. South Africa Liquid Biopsy Market Share (%), By Usage, 2017-2031F
  • Figure 285. South Africa Liquid Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 286. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 287. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 288. By Sample Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 289. By Circulating Biomarker Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 290. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 291. By Usage Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 292. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 293. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023